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Six-transmembrane epithelial antigen of the prostate 4 (STEAP4) is a metalloreductase that has 
been shown previously to protect cells from inflammatory damage. Genetic variants in STEAP4 
have been associated with numerous metabolic disorders related to obesity, including putative 
defects in the acute insulin response to glucose in type 2 diabetes (T2D). Purpose: We examined 
whether obesity and/or T2D altered STEAP4 expression in human pancreatic islets. Methods: 
Human islets were isolated from deceased donors at two medical centers and processed for 
quantitative PCR. Organ donors were selected by status as non-diabetic or having T2D. Site1 
(Edmonton): N=13 T2D donors (7M, 6F), N=20 non-diabetic donors (7M, 13F). Site2 
(Virginia): N=6 T2D donors (6F), N=6 non-diabetic donors (3M, 3F). Results: STEAP4 showed 
reduced islet expression with increasing BMI among all donors (P<0.10) and non-diabetic 
donors (P<0.05) from Site1; STEAP4 showed reduced islet expression among T2D donors with 
increasing HbA1c. Islet STEAP4 expression was also marginally higher in female donors 
(p<0.10). Among T2D donors from Site2, islet insulin expression was reduced, STEAP4 
expression was increased, and white blood cell counts were increased compared to non-diabetic 
donors. Islets from non-diabetic donors that were exposed overnight to 5ng/ml IL-1β displayed 
increased STEAP4 expression, consistent with STEAP4 upregulation by inflammatory signaling. 
Conclusions: These findings suggest that increased STEAP4 mRNA expression is associated 
with inflammatory stimuli, whereas lower STEAP4 expression is associated with obesity in 
human islets. Given its putative protective role, downregulation of STEAP4 by chronic obesity 




The intersection between low-grade inflammation and beta-cell dysfunction has gained 
increased interest in recent years as a key factor in the pathophysiology of type 2 diabetes (T2D). 
It has previously been shown that islets from T2D donors demonstrate inflammatory changes at 
the histological level [1–4], and an inflammatory milieu heightens the risk for T2D development 
in prospective clinical studies [5].   
A potential player in this intersection is six-transmembrane epithelial antigen of the 
prostate 4 (STEAP4; also called STAMP2 [6] or TIARP [7]). A number of genome-wide 
association studies suggest that STEAP4 is involved with numerous disorders related to obesity 
and metabolism including insulin resistance [8,9], metabolic syndrome [10,11], and insulin 
levels [12,13]. Beyond its known role as a metalloreductase [14], studies have shown that 
STEAP4 plays an anti-inflammatory or protective role from cellular damage in adipocytes 
[15,9], mesangial cells [16], hepatocytes [17–19], and synoviocytes [20]. In studies of mice, the 
STEAP4-/- phenotype includes the spontaneous development of obesity, insulin resistance, and 
eventual hyperglycemia [21], as well as signs of atherosclerosis [22], also suggesting a protective 
role for the protein. 
 The limited data in humans generated thus far have been conflicting. Human abdominal 
subcutaneous and omental white adipose tissue collected from insulin-resistant individuals was 
associated with increased STEAP4 levels in a pair of studies [23,24]. By contrast, several similar 
studies have demonstrated decreased STEAP4 expression in visceral adipose tissue with 
increased adiposity or body mass index (BMI) [25–28]. 
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Our laboratory has recently demonstrated that STEAP4 is expressed in rodent islets and 
strongly upregulated in response to low-grade inflammation [13]. Further, single nucleotide 
polymorphisms in STEAP4 have been associated with differences in acute insulin response to 
glucose (AIRg) in a human population prone to obesity and T2D [13], suggesting a role for 
STEAP4 in pancreatic islet function in obesity and/or T2D. In the present study, we compared 
STEAP4 expression in human islets collected from T2D donors and non-diabetic controls from 
two different sites to determine what factors are associated with differences in STEAP4 
expression at the islet level.  
 
 
Materials and Methods 
Human islet isolations at University of Alberta (Edmonton) 
Human islets were isolated from donor organs at the Alberta Diabetes Institute IsletCore 
(www.bcell.org/IsletCore.html) or the Clinical Islet Laboratory at the University of Alberta as 
described [29] and cultured as described [30]. Information on donor age, BMI, sex and HbA1c 
were provided.  
 
Human islet isolation at University of Virginia (Virginia) 
Human pancreatic islets were isolated at the University of Virginia cell processing 
facility. Under GMP conditions, pancreata were cleaned of extraneous tissue; inflated with 
Liberase MTF collagenase and digested using the Ricordi method. Digestate was washed and 
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pelleted for purification. Purification was performed using a COBE 2991 cell processor with a 
continuous Biocoll gradient. Purified pancreatic islets were cultured in CMRL media 
supplemented with 10% human albumin, nicotinomide and glutathione. Cultured islets were 
considered high purity if purity was 85% or above. 
Select medical data were available for human islets sourced from University of Virginia 
consisting of basic demographic information and results of laboratory studies performed during 
hospital admission prior to death. The following serum studies were analyzed across the donor 
set: sodium, potassium, chloride, bicarbonate, blood urea nitrogen, creatinine, glucose, calcium, 
albumin, international standardized ratio (INR), lipase, white blood count, and hemoglobin. 
Several sets of values were available for each donor, as multiple iterations had been performed 
during hospitalization. The maximum, minimum, average, and final values of each study 
category were compiled and compared by scatter plot with islet STEAP4 expression values.  
 
RNA isolation and qPCR of human islet samples 
For the Edmonton samples, islets were hand-picked to >99% purity and RNA was 
extracted using TRIzol Reagent (ThermoFisher Scientific, Burlington, ON. Canada) and reverse 
transcription performed using 5X All-in-One RT Master Mix (Applied Biological Materials Inc, 
Richmond, BC. Canada). qPCR was performed on a 7900HT Fast Real-Time PCR System using 
Fast SYBR Green Master Mix (ThermoFisher Scientific) and primers listed below.   
For the Virginia samples, RNA isolations were performed using an AllPrep 
DNA/RNA/Protein mini Kit from Qiagen GmbH (Hilden, Germany) and reverse transcription of 
0.25-1µg RNA using a High Capacity cDNA kit (Life Technologies). qPCR was performed 
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using iQ SYBR green SuperMix (Bio-Rad, Hercules, CA, USA) on an iCycler (MyiQ Optical 
Module) Bio-Rad system. mRNA expression was quantified based on the HPRT1 house-keeping 
gene, using the Relative Expression Software Tool [31]. Outliers were removed based on their 
relation to the interquartile range (IQR). Specifically, gene expression less than [First Quartile 
(Q1) – 1.5*IQR] or greater than [Third Quartile (Q3) + 1.5*IQR] were considered outliers. The 
following key primer sets were used: for hHPRT1, forward (5′-
ATGGACAGGACTGAACGTCT-3′) and reverse (5′-TCCAGCAGGTCAGCAAAGAA-3′); for 
insulin, forward (5′-TGCGGGGAACGAGGCTTCTTCTA-3′) and reverse (5′-
AGGGACCCCTCCAGGGCCAAG-3′); for STEAP4, forward (5′-
GCGCCTCTCCCTCAGTTATG-3′) and reverse (5′-GGTCTTCTGGGGGTTTCGAC-3′). A full 
list of primers is included as Supplemental Table S1.  
Note that STEAP4 values were normalized to HPRT1 gene for both the Edmonton and 
Virginia data sets. STEAP4 expression patterns in the Edmonton group were also normalized to 
18s, but similar results were observed with either control. For the data reported here, STEAP4 
expression was normalized to HPRT1 unless otherwise stated. 
 
Statistics 
Correlations between STEAP4 and chart data were made by Pearson correlation. 
GraphPad Prism software was used to determine p-values for linear regression analysis. A two-






Site-related differences in STEAP4 expression 
 The same primers were used at both islet isolation sites to measure STEAP4 mRNA and 
HPRT1 control mRNA, however, STEAP4 expression among all donors from the Edmonton site 
was 4.1+/-0.2 fold over the HPRT1 values versus 2.1+/-0.4 for the Virginia site (P=0.0003). Due 
to this disparity between data sets, we analyzed the data from each site separately. We have also 
provided the results of analysis using the combined data sets from both sites in Supplemental 
Table S2 for comparison.  
   
Donor Characteristics from University of Alberta (Edmonton) 
We examined islets from n=20 non-T2D donors and n=13 T2D donors isolated at the 
University of Alberta (Edmonton). As shown in Table 1, no differences in age or body mass 
index (BMI) among T2D vs non-T2D donors were observed. Glycosylated hemoglobin (HbA1c) 
was significantly higher among donors with T2D. 
T2D donors tended to be older than non-T2D donors, but differences did not reach 
statistical significance. Scatter plot analysis across all ages produced a correlation coefficient of 
R2=0.002 with STEAP4 expression (not significant).  In addition, among donors 60 years of age 
and over (the highest quartile), STEAP4 expression levels were 4.0+/-0.6 fold of the HPRT1 
house-keeping gene, whereas STEAP4 levels for donors 40 years of age or under (lowest 




Decreased STEAP4 expression is associated with increased BMI (Edmonton) 
Initial observations showed no statistically significant differences between islets isolated 
from non-T2D donors (4.1+/-0.3, n=20) and T2D donors (4.0+/-0.4, n=13). We next analyzed 
BMI as a categorical variable and grouped T2D and non-T2D donors as lean (BMI≤25), 
overweight (25>BMI≤30), or obese (BMI>30). In this analysis among all donors from Site 1, 
STEAP4 expression was marginally reduced (P<0.10) in obese compared to lean donors (Figure 
1A). This relationship was more apparent among non-T2D donors, where islets from obese 
donors had significantly reduced STEAP4 expression compared to lean and overweight donors 
(Figure 1B). These findings are consistent with several studies showing that STEAP4 levels in 
adipose tissue decrease with increasing adiposity [25–27].  Surprisingly, no significant changes 
in STEAP4 expression were observed among T2D islet donors between lean, overweight, and 
obese categories, as shown in Figure 1C. When evaluated as a continuous variable, BMI was 
significantly correlated with reduced STEAP4 levels for all donors combined (Figure 1D), for 
non-T2D donors (Figure 1E), but not for T2D donors (Figure 1F).  
 
 
STEAP4 expression is reduced with increasing HbA1C in T2D donors (Edmonton) 
We next examined the relationship between STEAP4 expression and HbA1c. As shown 
in Figure 2A, HbA1c was elevated among T2D donors (see also Table 1), but there were no 
overall differences in STEAP4 expression levels between T2D and non-T2D donors. When 
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examined by scatter plot, STEAP4 showed no relationship with HbA1c among islets from all 
donors (P=0.17) or among non-T2D donors (Figure 2B). In contrast, STEAP4 was negatively 
correlated with HbA1C (P=0.01) among T2D donors, as shown in Figure 2C.  
 
STEAP4 expression is higher in female donors compared to male donors 
 We also examined STEAP4 expression for possible differences between male and female 
donors. Combining both T2D and non-T2D donor islets in the Edmonton group, the fold change 
for STEAP4 expression over the housekeeping gene HPRT1 in islets from female donors (4.4 +/- 
0.3, n=19) was marginally higher than in islets from male donors (3.6 +/-0.4, n=14, P<0.10). 
STEAP4 levels were slightly higher in islets from female donors compared to male donors for 
both non-T2D and T2D subsets, but these differences were not significant. Higher STEAP4 
levels were also observed in islets from female donors in the Virginia group (Female: 2.6+/-0.5, 
n=8 vs. Male: 0.7+/-0.2, n=3, P<0.01, see also Table 2) and when both data sets from Site 1 and 
Site 2 were combined (P<0.10, see Supplemental Table S2). STEAP4 expression levels thus 
appear to be consistently higher in islets from females compared to males, although the 
significant of these differences is marginal (p-values of 0.05-0.10 in most comparisons).   
 
Donor characteristics from the University of Virginia and STEAP4 correlations (Virginia) 
Studies were also performed on islet STEAP4 expression levels with a donor base from 
Virginia. Clinical chart data from hospitalizations prior to death were available for most tissue 
donors from Virginia.  A summary of key demographic information is shown in (Table 2). 
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Tissue samples were obtained from a total of N=7 females and N=3 males. Notably, all five 
donors from the T2D group were female. The cause of death for the majority of donors was 
cerebrovascular accident (CVA).  Anoxia, central nervous system (CNS) tumor, and cervical 
fracture accounted for the deaths of the three other donors, respectively. There were no 
significant differences in age or BMI between the two groups.  
Analysis of chart data yielded a number of significant differences. STEAP4 expression 
levels correlated strongly to maximum serum sodium (R2 = 0.6279, p = 0.006) and maximum 
serum chloride (R2 = 0.704, p = 0.002) as shown in Figure 3A and Figure 3B. “Maximum” 
refers to the highest value recorded among multiple measures while in hospital.  A borderline 
significant correlation to STEAP4 was also observed for mean sodium (R2 = 0.3801, p = 0.06) 
and mean chloride (R2 = 0.3794, p = 0.06). This correlation may indicate STEAP4 upregulation 
related to the acute patient condition in hospital. 
Mean white blood cell (WBC) counts differed markedly between T2D and non-T2D 
donor populations, as shown in Table 2.  Maximum WBC count (p = 0.004, Figure 3C) and last 
WBC (p = 0.004) also differed between the two groups, with higher counts found in the T2D 
group.   
 
STEAP4 is upregulated by exposure to interleukin 1-beta (Virginia) 
Since STEAP4 is highly sensitive to cytokine-induced expression and inflammatory 
signaling [7,13,32], we examined whether exposure to proinflammatory conditions could directly 
increase STEAP4 expression in human islets. We exposed islets from 3 non-T2D donors to 5 
ng/ml IL-1β + 25mM glucose conditions overnight and then collected mRNA to measure 
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STEAP4 expression levels. As shown in Figure 3D, STEAP4 expression was markedly 
upregulated compared to untreated controls.  In contrast to chronic obesity or hyperglycemia 
downregulating STEAP4 expression, these data suggest an increase in inflammation or immune 
response may be responsible for the increased STEAP4 expression. Note that 25mM glucose 
exposure could be regarded as a hyperglycemic trigger of STEAP4 in addition to IL-1β. We 
showed in rodent islets, however, that chronic high glucose exposure has little impact on 
STEAP4 levels [13], especially compared to cytokine effects.  
 
STEAP4 gene expression in comparison to key markers of islet function (Virginia) 
Expression levels of the following known pancreatic islet genes were quantified in 
relation to the HPRT1 housekeeping gene: STEAP4, genes related to secretory hormones 
(insulin, glucagon), genes related to maintenance of normal islet function (GLUT1, GLUT2, 
PDX1, NKX6-1, KCNJ11), genes related to insulin signaling pathways (GLP1R, INSR, IRS2, 
IGF1R), and genes related to metabolism (CITED2, ACC1, ACC2, FASN, SCD1). The fold 
change in mRNA expression between donors with T2D and donors without T2D are shown in 
Figure 4A.  
Among all 17 genes examined, only insulin (p = 0.04) and STEAP4 (p = 0.03) showed 
significant differences between donor populations. Islets from donors with T2D expressed 
significantly lower levels of insulin (expected for individuals with T2D) and significantly higher 
levels of STEAP4 compared to islets from non-diabetic donors. However, there was a strong 
relationship between STEAP4 expression and insulin expression (R2 = 0.90, p = 0.01, n=5) in the 
T2D population, with low levels of insulin correlated with low levels of STEAP4 expression in 
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islets. Since loss of insulin is related to hyperglycemia, the reduced STEAP4 levels with low 
insulin is consistent with the lower STEAP4 with increased HbA1c observed in the Edmonton 
data. Notably, one outlier from the T2D group was included in Table 2 but excluded from all 
analysis due to exceptionally high STEAP4 expression (fold change of 26.61); the high 
expression did not appear to correlate with unusual values in any other measured parameter.  
  
Discussion 
This is the first study to show that STEAP4 is expressed in the human pancreatic islet. 
Our data suggest that multiple regulatory factors contribute to increased or decreased STEAP4 
expression, as depicted in Figure 4B. Known and putative upregulating factors include pro-
inflammatory cytokines [7,13,32,33], nutrient intake [21], and acute cellular stress [13,21]. 
Downregulating factors of STEAP4 include obesity [25–28], HbA1c/diabetic condition [26], and 
chronic inflammation.  We discuss below how these putative competing regulatory factors may 
impact islet STEAP4 expression.  
 
STEAP4 expression in obesity  
The relationship between STEAP4 and obesity is not entirely clear due to conflicting 
findings in the literature. A pair of studies showed that STEAP4 levels in adipocytes and white 
adipose tissue were increased in obesity [23,24], whereas other studies showed that STEAP4 was 
downregulated in obese people [25–28]. In yet another study, STEAP4 gene expression in both 
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fat and muscle was reduced among the most insulin resistant individuals independent of BMI 
[34].   
With regard to islets, we showed a clear and significant decrease in STEAP4 with 
increasing BMI, especially among non-T2D donors (Edmonton, Site 1). T2D donors in the 
Edmonton group were skewed toward higher BMI with only N=2 lean donors (BMI <25), thus 
potentially masking a relationship.  STEAP4 levels in T2D donors were decreased with 
increasing HbA1c, suggesting an inverse relationship between STEAP4 expression and severity 
of hyperglycemia.  For the Virginia data (site 2), determining a relationship between STEAP4 
expression and BMI was not statistically feasible due to the smaller sample size and relatively 
tight distribution of BMI values (10 of 12 donors were non-obese, (<30 BMI)). Even with these 
limitations, trend lines pointed to an inverse relationship between STEAP4 expression and BMI 
for both T2D and non-T2D donors, thus supporting the Edmonton findings.  
 
STEAP4 expression and acute vs. chronic inflammation 
Because obesity is associated with chronic low-grade inflammation and therefore 
elevated cytokine levels, reduced STEAP4 expression with increased obesity seems 
counterintuitive to previous research showing upregulation of STEAP4 in the presence of 
cytokines [7,13,32,33].  Our data show that direct overnight exposure to pro-inflammatory 
cytokines (5 ng/ml IL-1β) increases expression of STEAP4 in human islets from non-T2D 
donors, supporting previous studies [7,13,32,33].  Note that glucose was also elevated for the 
overnight cytokine treatment, but high glucose alone does not appear to increase STEAP4 
expression in islets [13]. We also showed that T2D donors from the Virginia cohort had 
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increased WBC counts compared to non-T2D controls, which may be indicative of an acute 
immune response. Sodium and chloride values were also associated with increased STEAP4 
expression, indicating a possible relationship to dehydration and/or inflammation. Overall, these 
data are consistent with an increase in STEAP4 in acute inflammatory circumstances.  
The reduced STEAP4 levels with elevated BMI may be due to chronic aspects of obesity, 
such as chronic low-grade inflammation, causing STEAP4 downregulation. Of interest, STEAP4 
levels are lower in circulating macrophages of women with metabolic syndrome compared to 
controls [35], suggesting downregulation of STEAP4 in inflammatory cells in chronic metabolic 
diseases.  Thus, differences in STEAP4 expression may be due, at least in part, to differences 
between chronic and acute inflammation with regard to cytokine dose, duration, and milieu [36].  
 
Male vs. Female 
Islets from female donors in the Edmonton cohort generally showed higher STEAP4 
expression compared to male donors. All Virginia T2D donors were female, while the non-T2D 
donors had equal male and female inclusion (n=3 each). It should be noted that the three lowest 
STEAP4 values among all n=11 donors from the Virginia cohort were all the male samples (See 
Table 2). Therefore, sex differences could explain, in part, why the STEAP4 expression in the 
Virginia T2D donors was higher than in non-T2D donors.  
The underlying physiological reason for differences in islet STEAP4 expression between 
sexes is not known. It is significant to note that women with metabolic syndrome (MetS) show 
down regulation in STEAP4 expression compared to non-MetS, while men show no significant 
differences in expression between those with MetS vs. those without [35]. Other regulating 
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factors to consider are hormones such as testosterone, which upregulates the expression of 
STEAP4 [37]. 
 
Additional Considerations and Limitations 
The differences in STEAP4 expression between the Edmonton site and Virginia site 
warrant additional discussion. A limitation of our study is that donor data sets were not 
equivalent. Thus, analysis and data presentation for each site were performed separately and 
were difficult to combine. For example, WBC count was known for Virginia, but not Edmonton, 
thus complicating analysis of the role of inflammation in both cohorts. The Virginia cohort did 
not provide sufficient statistical power to account for sex, BMI, or hemoglobin A1c. In addition, 
therapeutic interventions between donors groups, disease management of donors, medical status 
at death, and even differences in health care systems between countries [38] could contribute to 
the observed differences in STEAP4 expression. What we have attempted to do is to identify 
factors for which we could find a strong correlation with STEAP4 expression, while 
acknowledging other potential confounding factors. 
The islet isolation procedures between sites also differed, resulting in potential 
differences in islet viability and function. Importantly, islets from Edmonton were hand-picked 
>99% purity, whereas the Virginia islets were purified to >85%, resulting in different levels of 
acinar tissue in the samples that could impact gene expression levels. Note that the islets 
themselves are composed predominantly of insulin-secreting beta-cells, glucagon-secreting 
alpha-cells, and somatostatin-secreting delta-cells [39,40], but the proportions of these cell types 
may differ from donor to donor, which could also impact expression. While differences in islet 
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purity may contribute to differences in results between sites, we observed more similarities than 
differences when comparable between sites, as discussed above. 
 
Conclusions 
Several studies suggest that STEAP4 plays a protective role in the face of inflammatory 
stress in models of metabolic disorders [9,21,22,41,42].  Thus, if obesity results in reduced 
STEAP4 expression levels, this may depress a normal compensatory responses to cellular stress. 
Moreover, reduced STEAP4 could directly impact insulin secretory function. Genetic variants in 
STEAP4 have been associated differences in the AIRg (also called first phase) in a diabetes-
prone population [13]. Our overall findings suggest that STEAP4 expression is downregulated 
by factors such as chronic obesity (BMI) and hyperglycemia (HbA1c) but upregulated by acute 
inflammation or cytokine exposure at the level of the pancreatic islet (see Figure 4B). These 
findings point to complex regulatory inputs to STEAP4, a protein that is increasingly associated 
with a protective role in metabolic disorders. Continued work toward elucidating what regulates 
STEAP4 and what role STEAP4 plays in metabolic disorders is warranted.  
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Table 1. Age, male and female donor number, BMI and HbA1c values for T2D and non-T2D 
donors from University of Alberta (Edmonton, Site 1). 
 
Table 2. Age, BMI, average white blood cell (WBC) count, sex, cause of death, and islet 
STEAP4 expression levels for donors diagnosed with or without T2D from University of 
Virginia (Virginia, Site 2). N/A = lab results were not available. * indicates STEAP4 value was 
listed but was removed as an outlier for all statistical comparisons.  
 
Figure 1. STEAP4 is negatively correlated with BMI. (A) STEAP4 expression levels for all 
donors from Site 1 (Edmonton) divided into lean (BMI≤25, N=9), overweight (25>BMI≤30, 
N=11), and obese (BMI>30, N=13). (B) STEAP4 expression levels for non-T2D donors divided 
into lean (N=7), overweight (N=6), and obese (N=7). (C) STEAP4 expression levels for T2D 
donors divided into lean (N=2), overweight (N=5), and obese (N=6). (D-F) Scatter plots for 
STEAP4 expression vs BMI for all donors (D) non-T2D donors (E) and T2D donors (F). 
*P<0.05,  #P<0.10. R2 and p-values provided in lower left corner of (D-F).  
Figure 2. STEAP4 is negatively correlated with HbA1c in T2D donors. (A) Mean HbA1c (left 
columns) and STEAP4 gene expression (right columns) for non-T2D (white columns) and T2D 
(black columns) donors (**P<0.01). (B-C) Scatter plots for STEAP4 expression vs HbA1c for 
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non-T2D donors (B) and T2D donors (C). R2 and p-values provided in lower right corner of (B) 
and (C). 
 
Figure 3. STEAP4 associations with sodium levels, chloride levels, and inflammatory status. (A-
B) Scatter plots for STEAP4 expression vs maximum sodium (A) and maximum chloride (B) for 
islet donors recorded during hospitalization (N=10). R2 and p-values provided in lower right 
corner. (C) White blood cell counts in non-T2D (N=5) and T2D donors (N=4). (D) STEAP4 
expression in islets isolated from N=3 donors treated overnight (24 hours) with 5ng/ml 
interleukin-1beta in 25mM glucose or untreated. *P<0.05, **P<0.01. 
 
Figure 4. (A) Gene expression differences in islets from non-T2D (N=5) vs. T2D donors (N=5) 
for a total of 17 genes related to islet function. *P<0.05. (B) Depiction of factors regulating 







Table 1. Donor Information: University of Alberta 
 
 
Table 2. Donor Information: University of Virginia 
 
Age Male Female BMI HbA1c
T2D 54.3 +/- 2.7 N=7 N=6 31.2 +/- 1.7 7.4 +/- 0.4
Non-T2D 46.9 +/- 2.9 N=7 N=13 29.2 +/- 1.5 5.7 +/- 0.1























Table S1. List of Primers 
 Primer name Sequence 
h18s rRNAf 5′-GGAGTATGGTTGCAAAGCTGA-3′ 



































hSTEAP4f  5′-GCGCCTCTCCCTCAGTTATG-3′ 
hSTEAP4r  5′-GGTCTTCTGGGGGTTTCGAC-3′ 
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Results of combined analysis of Site 1 and Site 2.  
 STEAP4 expression from the Edmonton site was 4.1+/-0.2 fold over the HPRT1 values 
versus 2.1+/-0.4 for the Virginia site (P=0.0003). Due to this disparity between data sets, we 
analyzed the data from each site separately. Table S2 below contains additional analysis of key 
findings from the paper using the combined data sets from Site 1 and Site 2 for comparison with 
the data presented in the main body of the publication. Note that by combining these data, the 
overall variance is increased, thus negatively impacting the statistical significance of any 
comparisons.  
 
Table S2. Combined data from Site 1 and Site 2.    
 STEAP4 expression levels (fold change of HRPT1) 
Data sets Non-T2D only T2D only Non-T2D + T2D 
    
Lean 3.8±0.6  (n=10) 4.5±1.6  (n=2) 3.9±0.6  (n=12) 
Overweight 3.5±0.7  (n=8) 3.6±0.70.4  (n=9) 3.6±0.4  (n=17) 
Obese 2.9±0.4  (n=8) 3.0±0.7  (n=8)   3.2±0.4  (n=16) 
    
Age (over 55) 3.1±0.6  (n=10) 4.3±0.5  (n=11) 3.7±0.5  (n=21) 
Age (under 45) 3.6±0.6  (n=10)   3.3±0.7  (n=3) 3.5±0.4  (n=13) 
    
Female #3.9±0.4  (n=16) 3.8±0.6  (n=11) #3.9±0.3  (n=27) 
Male #2.7±0.6  (n=10) 3.5±0.6  (n=8) #3.0±0.4  (n=18) 
 
Sample size for each data point is included in parentheses. Note that the age cutoffs were 
adjusted to include more samples from Site 2 (Virginia) in the analysis. Because HbA1c values 
were not available for samples from Site 2, so combined analysis was not possible. * indicates P-
value difference between groups of <0.05. # indicates P-value difference between 0.05 and 0.10 
for male vs female comparison. 
The author has requested enhancement of the downloaded file. All in-text references underlined in blue are linked to publications on ResearchGate.
